DNA vectors. Precedents and safety.
Merck Institute for Therapeutic Research, Merck Research Laboratories (WP 53C-350), West Point, Pennsylvania 19486, USA.
M R
MR
Hilleman
D000818:Animals; D002478:Cells, Cultured / Q000821:virology; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000235:genetics; D003673:Defective Viruses / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D008322:Mammals / Q000821:virology; D009369:Neoplasms / Q000209:etiology; D010957:Plasmids / Q000235:genetics; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology*; D011995:Recombination, Genetic; D012190:Retroviridae / Q000235:genetics / Q000472:pathogenicity / Q000502:physiology; D014412:Tumor Virus Infections / Q000635:transmission; D014611:Vaccination / Q000009:adverse effects / Q000379:methods* / Q000639:trends; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000145:classification; D014765:Viral Vaccines / Q000009:adverse effects / Q000145:classification; D014774:Virulence; D014779:Virus Replication
D004274:DNA, Recombinant; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines